Diabetes mellitus, commonly referred to as diabetes, is the 8th leading cause of death worldwide. As of 2015, approximately 415 million people were estimated to be diabetic worldwide, type 2 diabetes being the most common accounting for approximately 90-95% of all diagnosed cases with increasing prevalence. Fructose-1,6-bisphosphatase is one of the important therapeutic targets recently discovered to treat this chronic disease. In this focused review, we have highlighted recent advances and structure-activity relationship studies in the discovery and development of different fructose-1,6-bisphosphatase inhibitors reported since the year 2000.
Keywords: Fructose-1,6-bisphosphatase inhibitors; adenosine 5’-monophosphate; chronic disease; diabetes mellitus; hyperglycemia; type 2 diabetes..
Copyright© Bentham Science Publishers; For any queries, please email at [email protected].